New drug interaction study for myelofibrosis treatment begins
NCT ID NCT06024915
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 1 trial in 40 healthy adults tests how TQ05105, a drug for myelofibrosis, interacts with other medications that affect liver enzymes. Participants take TQ05105 alone and then with either itraconazole or rifampicin to see how these drugs change TQ05105 levels in the body. The goal is to understand safety and dosing for future use in patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TQ05105 tablets (a JAK2 inhibitor)
What this could lead to
If successful, this study could help doctors understand how to safely combine TQ05105 with other medications for myelofibrosis patients.
What could go wrong
This is a very early phase 1 study in healthy volunteers, not patients. It only tests drug interactions, not whether TQ05105 works for myelofibrosis. Results may not predict real-world outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shandong Provincial Hospital
Jinan, Shandong, 250021, China